Όλο το DSpace

Πλοήγηση ανά Θέμα "airway obstruction"

Αποτελέσματα 1-6 από 6

    • Endocan and the respiratory system: A review 

      Kechagia M., Papassotiriou I., Gourgoulianis K.I. (2016)
      Endocan, formerly called endothelial cell-specific molecule 1, is an endothelial cell-associated proteoglycan that is preferentially expressed by renal and pulmonary endothelium. It is upregulated by proangiogenic molecules ...

    • Leukotriene antagonists: As firstline asthmatic therapy: A review 

      Wozniak, G.; Kotrotsiou, E.; Roupa, Z. (2005)
      Asthma is a chronic inflammatory disorder characterized by airflow obstruction. The development of leukotriene receptor antagonists and synthesis inhibitors in briefly described; and acute exercise, allergen, and aspirin ...

    • Pesticides and respiratory disorders in rural areas [2] 

      Gourgoulianis, K. I.; Molyvdas, P. A. (2002)

    • Prognostic assessment in COPD without lung function: The B-AE-D indices 

      Boeck L., Soriano J.B., Brusse-Keizer M., Blasi F., Kostikas K., Boersma W., Milenkovic B., Louis R., Lacoma A., Djamin R., Aerts J., Torres A., Rohde G., Welte T., Martinez-Camblor P., Rakic J., Scherr A., Koller M., Van Der Palen J., Marin J.M., Alfageme I., Almagro P., Casanova C., Esteban C., Soler-Cataluña J.J., De-Torres J.P., Miravitlles M., Celli B.R., Tamm M., Stolz D. (2016)
      Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide ...

    • Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD 

      Stolz D., Leeming D.J., Kristensen J.H.E., Karsdal M.A., Boersma W., Louis R., Milenkovic B., Kostikas K., Blasi F., Aerts J., Sand J.M.B., Wouters E.F.M., Rohde G., Prat C., Torres A., Welte T., Roth M., Papakonstantinou E., Tamm M. (2017)
      Background Extracellular matrix (ECM) remodeling of the lung tissue releases protein fragments into the blood, where they may be detected as serologic surrogate markers of disease activity in COPD. Our goal was to assess ...

    • Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD 

      Baumeler L., Papakonstantinou E., Milenkovic B., Lacoma A., Louis R., Aerts J.G., Welte T., Kostikas K., Blasi F., Boersma W., Torres A., Rohde G.G.U., Boeck L., Rakic J., Scherr A., Tamm M., Stolz D. (2016)
      Background and objective: Gastroesophageal reflux disease (GERD) symptoms are associated with a higher risk of chronic obstructive pulmonary disease (COPD) exacerbation. We hypothesize that treatment with proton pump ...